Manual de Hipertensión Arterial en la Práctica Clínica de ... - SAMFyC
Manual de Hipertensión Arterial en la Práctica Clínica de ... - SAMFyC
Manual de Hipertensión Arterial en la Práctica Clínica de ... - SAMFyC
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Manual</strong> <strong>de</strong> <strong>Hipert<strong>en</strong>sión</strong> <strong>Arterial</strong> <strong>en</strong> <strong>la</strong> <strong>Práctica</strong> <strong>Clínica</strong> <strong>de</strong> At<strong>en</strong>ción Primaria<br />
Terapia Combinada<br />
3. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S et al. Effects of int<strong>en</strong>sive<br />
blood pressure lowering and low-dose aspirin in pati<strong>en</strong>ts with hypert<strong>en</strong>sion: principal results of the<br />
Hypert<strong>en</strong>sion Optimal Treatm<strong>en</strong>t (HOT) randomised trial. HOT Study Group. Lancet 1998;<br />
351:1755-62<br />
4. Dahlof B, Devereux RB, Kjelds<strong>en</strong> SE, Julius S, Beevers G, Faire U et al. Cardiovascu<strong>la</strong>r morbidity and<br />
mortality in the Losartan Interv<strong>en</strong>tion For Endpoint reduction in hypert<strong>en</strong>sion study (LIFE): a<br />
randomised trial against at<strong>en</strong>olol. Lancet 2002; 359:995-1003<br />
5. Coca A. Evolución <strong>de</strong>l control <strong>de</strong> <strong>la</strong> hipert<strong>en</strong>sión arterial <strong>en</strong> España. Resultados <strong>de</strong>l Estudio<br />
Controlpres 98. <strong>Hipert<strong>en</strong>sión</strong> 1998; 15:298-307<br />
6. Divisón Garronte JA, Panero Hidalgo P, Barrios Alonso V. Tratami<strong>en</strong>to Farmacológico <strong>de</strong> <strong>la</strong><br />
<strong>Hipert<strong>en</strong>sión</strong> <strong>Arterial</strong>. En: Alonso Mor<strong>en</strong>o FJ, Divisón Garrote JA, Llisteri Car JL, Lou Arnarl S,<br />
Rodríguez Roca GC. Nuevas Estrategias <strong>en</strong> HTA. 1ª edición. Madrid. FAES FARMA. 2005. 65 – 77.<br />
7. Mancia G, Fail<strong>la</strong> M, Grappiolo A, Giannattasio C. Pres<strong>en</strong>t and future role of combination treatm<strong>en</strong>t<br />
in hypert<strong>en</strong>sion. J Cardiovasc Pharmacol 1998;31(Suppl 2):S41-4<br />
8. The Sixth Report of the Joint National Committee on Prev<strong>en</strong>tion, Detection, Evaluation and<br />
Treatm<strong>en</strong>t of High. Arch Intern Med 1997; 157: 2413-2427<br />
9. Segura <strong>de</strong> <strong>la</strong> Mor<strong>en</strong>a J, Campo Si<strong>en</strong> C, Ruilope Urioste L M; Factores que influy<strong>en</strong> <strong>en</strong> <strong>la</strong> hipert<strong>en</strong>sión<br />
arterial refractaria. <strong>Hipert<strong>en</strong>sión</strong> 2002. 19(4): 163-71<br />
10. Holl<strong>en</strong>berg NK. AT (1)-receptor blocka<strong>de</strong> and the kidney: importance of non-ACE pathways in<br />
health and disease. J Hum Hypert<strong>en</strong>s 2002; 16(Suppl 3):S59-63<br />
11. Llisterri JL, Rodríguez G, Alonso FJ, Lou S, Divisón JA, Santos JA, et al. Control <strong>de</strong> <strong>la</strong> presión arterial<br />
<strong>en</strong> <strong>la</strong> pob<strong>la</strong>ción hipert<strong>en</strong>sa españo<strong>la</strong> at<strong>en</strong>dida <strong>en</strong> At<strong>en</strong>ción Primaria. Estudio PRESCAP 2002. Med<br />
Clin (Barc) 2004;122:165-71<br />
12. Brown MJ, Cruickshank JK, Dominiczak AF, MacGregor GA, Poulter NR, Russell GI, et al. Better<br />
blood pressure control: how to combine drugs. J Human Hypert<strong>en</strong>s 2003;17:81-6.<br />
13. Giner Galván V, Esteban Giner MJ, Forner Giner MJ, Redón I Mas J. Tratami<strong>en</strong>to farmacológico<br />
combinado <strong>en</strong> el manejo <strong>de</strong> <strong>la</strong> hipert<strong>en</strong>sión arterial crónica es<strong>en</strong>cial. <strong>Hipert<strong>en</strong>sión</strong> 2004. 21(3): 139-<br />
157.<br />
14. Mourad JJ, Waeberb, Zannad F, Lavilled M, Durue G, Andréjakf M. STRATHE. Comparación <strong>de</strong><br />
difer<strong>en</strong>tes estrategias terapéuticas <strong>en</strong> <strong>la</strong> hipert<strong>en</strong>sión: combinación a bajas dosis <strong>de</strong> Perindopril /<br />
indapamida fr<strong>en</strong>te a una terapia secu<strong>en</strong>cial o a una terapia aditiva. J Hypert<strong>en</strong>s 2004, 22:2379–<br />
2386.<br />
Grupo <strong>de</strong> <strong>Hipert<strong>en</strong>sión</strong> <strong>Arterial</strong><br />
Sociedad Andaluza <strong>de</strong> Medicina <strong>de</strong> Familia<br />
90